Celldex Therapeutics Inc

Latest Results (10.01.2025):

Revenue Growth

In the third quarter of 2024, Celldex Therapeutics Inc. reported total revenues of $3.2 million, a significant increase from the $1.5 million reported in the same quarter of 2023. For the nine months ended September 30, 2024, total revenues were $5.8 million, compared to $2.8 million for the same period in 2023.

Research and Development Expenses

Celldex Therapeutics Inc. incurred research and development expenses of $45.3 million in the third quarter of 2024, up from $34.5 million in the third quarter of 2023. For the nine months ended September 30, 2024, R&D expenses totaled $116.6 million, compared to $87.6 million for the same period in 2023.

General and Administrative Expenses

General and administrative expenses for Celldex Therapeutics Inc. were $10.1 million in the third quarter of 2024, compared to $8.2 million in the same quarter of 2023. For the nine months ended September 30, 2024, G&A expenses were $28.3 million, up from $22.1 million for the comparable period in 2023.

Net Loss

Celldex Therapeutics Inc. reported a net loss of $42.1 million, or ($0.64) per share, for the third quarter of 2024. This compares to a net loss of $38.3 million, or ($0.81) per share, for the third quarter of 2023. For the nine months ended September 30, 2024, the net loss was $110.8 million, or ($1.74) per share, compared to $98.1 million, or ($2.08) per share, for the same period in 2023.

Financial Outlook

Celldex Therapeutics Inc. believes that its cash, cash equivalents, and marketable securities, which totaled $756.0 million as of September 30, 2024, are sufficient to meet estimated working capital requirements and fund current planned operations through 2027.